SIGA Technologies, Inc.

NasdaqGM SIGA

SIGA Technologies, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2024: USD 173.73 M

SIGA Technologies, Inc. Revenue is USD 173.73 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 399.31% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

SIGA Technologies, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 34.79 M, a -83.80% change year over year.
SIGA Technologies, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 214.77 M, a 283.24% change year over year.
SIGA Technologies, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 56.04 M, a -38.75% change year over year.
SIGA Technologies, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 91.49 M, a 280.47% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

NasdaqGM: SIGA

SIGA Technologies, Inc.

CEO	Dr. Diem Nguyen M.B.A., Ph.D.
IPO Date	Sept. 10, 1997
Location	United States
Headquarters	31 East 62nd Street
Employees	45
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.

Key trends

Past 5 years